Abstract:OBJECTIVE To investigate the effects of human telomerase reverse transcriptase (hTERT) promoter and survivin promoter in tumor-specific gene therapy. METHODS hTERT promoter and survivin promoter were obtained by PCR using Jurkat genomic DNA. Recombinant adeno-associated virus (AAV) vectors containing exogenous TRAIL gene and hTERT promoter or survivin promoter were constructed and designated as rAAV-hTERT-TRAIL (h/TRAIL) or rAAV-survivin-TRAIL (s/TRAIL). rAAV particles were obtained after packing and purification and the virus titer was calculated by real-time PCR. Human hepatocellular carcinoma (HCC) cells of the lines SMMC-7721, BEL-7402, HepG2, and Hep3B, and primary human hepatocytes (PHHs) were transfected with h/TRAIL or s/TRAIL. Flow cytometry was used to detect the expression of the reporter gene enhanced green fluorescent protein (EGFP), so as to examine the activity of the two promoters. MTT method was used to detect the activity of the cells. Fifteen BalB/C mice underwent subcutaneous injection of SMMC-7721 cells so as to establish tumor models and then were randomly divided into 3 groups to undergo intra-tumor injection of h/TRAIL, s/TRAIL, or PBS. The growth of tumor was observed for 5 weeks, and then peripheral blood samples were collected to examine the serum AST and ALT levels. TUNEL was used to detect the apoptosis if the tumor cells. RESULTS All the SMMC-7721, BEL-7402, HepG2, and Hep3B cells driven by both h/TRAIL and s/TRAIL showed EGFP expression, however, no fluorescence could be seen in the PHHs transfected with h/TRAIL and s/ TRAIL. MTT method showed that 72 hours after the transfection of h/TRAIL and s/TRAIL the survival rates of the SMMC-7721, BEL-7402, and HepG2 cells all decreased, however, the survival rate of the Hep3B cells and PHHs did not changed significantly. The size of the subcutaneous tumor of the mice of the h/ TRAIL group was 625 mm3, significantly smaller than that of the PBS group (1500 mm3, P <0.05), however, the tumor size of the s/TRAIL group was 1117 mm3, not significantly different from that of the PBS group (P >0.05). The AST and ALT levels of all mice did not change significantly 5 weeks after the intratumor injection. CONCLUSION Tumor-specific promoters are promising candidates in targeted tumor gene therapy.

Potent Antitumor Effect of Trail Mediated by A Novel Adeno-Associated Viral Vector Targeting to Telomerase Activity for Human Hepatocellular Carcinoma

Targeted Expression of Green Fluorescent Protein/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Fusion Protein from Human Telomerase Reverse Transcriptase Promoter Elicits Antitumor Activity Without Toxic Effects on Primary Human Hepatocytes

Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells

AAV-mediated TRAIL Gene Expression Driven by Htert Promoter Suppressed Human Hepatocellular Carcinoma Growth in Mice

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

Anti-liver Cancer Activity of TNF-related Apoptosis-Inducing Ligand Gene and Its Bystander Effects.

The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma

Antitumor Effect of a Novel Adeno-Associated Virus Vector Targeting to Telomerase Activity in Tumor Cells.

[Effects of Human Telomerase Reverse Transcriptase Promoter and Survivin Promoter in Targeted Tumor Gene Therapy].

Suppression of cancer growth in mice by adeno-associated virus vector-mediated IFN-β expression driven by hTERT promoter

Enhanced Antitumor Effect of Combining Interferon Beta with TRAIL Mediated by Tumor-Targeting Adeno-Associated Virus Vector on A549 Lung Cancer Xenograft.

Therapeutic Efficacy Of An Htert Promoter-Driven Oncolytic Adenovirus That Expresses Apoptin In Gastric Carcinoma

Fiber-modified Adenoviral Vector Expressing the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Gene from the Human Telomerase Reverse Transcriptase Promoter Induces Apoptosis in Human Hepatocellular Carcinoma Cells

Oral Adeno-Associated Virus-Strail Gene Therapy Suppresses Human Hepatocellular Carcinoma Growth in Mice

A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma

Conditionally Replicative Adenovirus Vector Carrying Trail Gene For Enhanced Oncolysis Of Human Hepatocellular Carcinoma

Recombinant Adeno-Associated Virus-Mediated Trail Gene Therapy Suppresses Liver Metastatic Tumors

Targeting Gene-Viro-Therapy with Afp Driving Apoptin Gene Shows Potent Antitumor Effect in Hepatocarcinoma

Suppressing Orthotopic Pancreatic Tumor Growth With A Fiber-Modified Adenovector Expressing The Trail Gene From The Human Telomerase Reverse Transcriptase Promoter

Potent Anti-Tumor Activity of Telomerase-Dependent and HSV-TK Armed Oncolytic Adenovirus for Non-Small Cell Lung Cancer in Vitro and in Vivo

[Expression of TRAIL(114-281) Mediated by Adeno-Associated Virus and Its Tumoricidal Activity].